Drug intelligence / Profile preview

Lactobacillus rhamnosus inm28-LR

Development stage: Preclinical
Lead developer: Inner Mongolia Agricultural University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus rhamnosus inm28-LR (also known as LR-inm28) is a specific probiotic strain isolated from the feces of a healthy centenarian in a longevity area in China. [11, 12] It has been systematically evaluated for its safety and probiotic potential. [11, 12] Research indicates that this strain exhibits strong adhesion to intestinal epithelial cells, tolerance to gastrointestinal conditions, and antimicrobial activity against pathogens. [12] Furthermore, it has demonstrated antioxidant and immunomodulatory properties. [12] Clinical and preclinical studies are exploring its effects on functional constipation in the elderly and its potential to improve learning and memory impairment in aging models by modulating gut microbiota and metabolites. [4, 5, 6, 7] The strain was developed by a team at the Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, at Inner Mongolia Agricultural University. [15, 17, 18]

Other names: 鼠李糖乳杆菌inm28-LR

Targets

TLR4 (Toll-like receptor 4)DC-SIGN (Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin)TLR9 (Toll-like receptor 9)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on Lactobacillus rhamnosus inm28-LR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus rhamnosus inm28-LR.

Explore the full profile